EPA or DHA: which omega-3 fatty acid matters for what

EPA and DHA are both long-chain omega-3 fatty acids, but in the body they partly take on different jobs. EPA is being studied in depression, among other things, and for targeted cardiovascular treatment; DHA is a major building block of the brain and retina. That does not add up to a simple rule of “EPA for the heart, DHA for the brain”: a biological role on its own does not prove that an extra supplement makes the organ in question work better.

What EPA and DHA are, and why their structure matters

Eicosapentaenoic acid, EPA for short, is made of 20 carbon atoms and has five double bonds. Docosahexaenoic acid, DHA, contains 22 carbon atoms and six double bonds. These differences affect how the fatty acids are built into membranes and converted into other molecules.

Among other things, EPA serves as the starting material for signaling molecules that regulate inflammation and other cellular responses. It can compete with arachidonic acid for certain enzymes. The resulting changes are more complex than simply switching inflammation off; a controlled course of inflammation and its resolution are also part of a normal immune response.

DHA is especially abundant in certain membranes of the brain and retina. There it influences their physical properties and the function of the proteins embedded in them. It is also the starting material for mediators such as protectins and certain resolvins. EPA supplies other specialized mediators, including E-series resolvins. So both fatty acids are involved in more than a single organ function.

The body can convert alpha-linolenic acid (ALA) from plants into EPA and DHA. This conversion is limited and varies from person to person. Commonly cited figures are below ten percent for EPA and considerably lower for DHA; they are not fixed rates that apply to everyone. Nor can EPA and DHA fully stand in for each other.

What studies show on mood and depression

A 2011 meta-analysis found stronger evidence of a reduction in depressive symptoms with preparations in which EPA made up at least 60 percent of the combined amount of EPA and DHA. DHA-dominant and other formulations showed less convincing results in that analysis.

That is a meaningful difference between the preparations studied. But it does not mean that EPA works in every case of depression, or that a particular ratio alone defines a treatment. The studies differ in concurrent therapy, baseline severity, dose and duration, among other things. Small head-to-head comparisons also should not be given more weight than the overall body of evidence, which is partly inconsistent.

Possible explanations under discussion include effects on inflammatory processes and on signaling in the nervous system. Some people with depression have a raised CRP level, but CRP is not an established single test for choosing EPA treatment. Likewise, a falling inflammation marker does not mean the depression is being adequately treated.

For persistent depressive symptoms, appropriate diagnostic and therapeutic care remains important. Omega-3 preparations may be discussed there as an add-on where appropriate. They should not lead anyone to put off effective psychotherapy or medication.

DHA for the brain, thinking and vision

DHA is a major component of neuronal membranes. How fluid those membranes are, and how their receptors and ion channels function, depends partly on their fatty acid composition. During pregnancy and early childhood, supply is especially relevant because the brain and visual function are developing.

In adults, observational studies show associations between omega-3 status and various measures of cognitive health. Such links can be a reason to run intervention studies. But they do not prove that an extra DHA capsule boosts memory or increases brain volume. Studies in older people and in people with mild cognitive impairment have produced mixed results.

Neuroprotectin D1, a signaling molecule made from DHA, is being studied in connection with cell protection, among other things. That makes DHA interesting for research on neurodegenerative diseases. However, the results of supplementation in Alzheimer’s disease are inconsistent. The explanation that treatment was simply started “too late” is a hypothesis, not sufficient evidence of a preventive effect.

In the retina, DHA is especially concentrated in the outer segments of the photoreceptors. It helps form the environment in which light-sensitive proteins such as rhodopsin work. Figures of more than half of certain fatty acid fractions refer to these specialized structures, not to the retina or the brain as a whole.

A 2024 meta-analysis looked at associations between fatty acid intake and age-related macular degeneration. An association in dietary data is a separate question from whether a supplement treats a disease that has already been diagnosed. Worsening vision should therefore be checked out regardless of whether someone takes omega-3.

Cardiovascular effects: similarities and differences

In sufficient amounts, both EPA and DHA can lower triglycerides. They also affect various vascular and cellular processes. Whether that translates into fewer heart attacks or strokes, however, has to be tested in studies that track those events.

The REDUCE-IT trial tested 4 g of icosapent ethyl daily, a purified prescription form of EPA, in 8,179 people on statin therapy with elevated triglycerides and high cardiovascular risk. Over a median of 4.9 years, the primary composite endpoint occurred in 17.2 percent of those on icosapent ethyl and 22.0 percent of those on placebo. That corresponds to an absolute difference of 4.8 percentage points and a relative risk reduction of 25 percent. At the same time, hospital admissions for atrial fibrillation or flutter were more common: 3.1 versus 2.1 percent.

This result is clinically relevant, but it applies to a specific drug in a specific risk group. It cannot be carried over to every fish oil capsule or to healthy people. Differences between studies of EPA alone and of EPA-DHA mixtures may also be shaped by the population, the comparator and other study details.

DHA can affect LDL cholesterol, blood pressure and other measurements differently from EPA. Individual changes, such as larger HDL particles, are not proof of a health benefit on their own. A cardiovascular decision rests on overall risk and established treatment, not just on one favorable lab value.

Amount, form and timing

What amounts have been studied?

Very different amounts are used for different goals. Depression studies often tested about 1 to 2 g of EPA daily; some cognitive studies used roughly 1 g of DHA, sometimes together with EPA. The 4 g in REDUCE-IT refers to a prescription treatment. These figures are not generally recommended daily amounts for healthy adults.

Dietary recommendations need to be kept apart from therapeutic doses: 1 to 2 g of EPA and DHA a day is not a general target for healthy adults. And safety assessments up to certain amounts do not mean those amounts make sense for everyone. At higher doses, atrial fibrillation, other medications and an individual’s bleeding risk all have to be taken into account, among other things.

Which form matters?

Omega-3 fatty acids are sold as triglycerides, re-esterified triglycerides, ethyl esters or in phospholipid-containing products. Absorption depends on the formulation and on the meal. Differences seen in pharmacokinetic studies, however, are not automatically differences in long-term health events.

Prescription drugs are standardized in active ingredient content and use. For supplements, transparent information on EPA, DHA, purity and oxidation control helps. Independent testing programs can provide additional information, but they do not guarantee an effect against any particular disease. Nor do price or dosage form add up to a universal quality ranking.

When to take it?

Taking it with a meal can improve absorption, especially for certain ethyl ester formulations, and helps some people tolerate it better. Whether morning or evening is better has been studied less. If burping or nausea is a problem, switching products or splitting the dose may make sense after talking it over with a professional.

What matters is that the actual daily amount stays clear. The amount per capsule and the manufacturer’s serving size are not always the same.

What ratio of EPA to DHA?

A ratio of 2:1 or 3:1 describes an EPA-dominant mix; 1:2 or 1:3 is DHA-dominant. Such figures describe a product, but they are not universal recipes for mood, memory or heart health.

For a comparison, what counts are the absolute amounts in milligrams and the data for the specific goal. A product with a high share of EPA can still contain very little EPA overall. Conversely, a balanced ratio is not automatically the best solution for every medical question.

Who might want to pay particular attention to EPA or DHA

In targeted cardiovascular drug treatment, EPA can play a role in the tested form and risk group. In depression, a possible add-on with EPA-dominant preparations is a question for the treatment plan. A CRP level above 2 mg/l on its own does not justify such a choice.

During pregnancy and breastfeeding, DHA supply is especially relevant because of the child’s development. Here too, the right intake depends on diet, local recommendations and individual care. For older people or those with a family history of dementia, on the other hand, no blanket preventive effect of a DHA supplement can be promised.

People who eat a vegan diet can get EPA and DHA directly from suitable algal oils. Some contain mainly DHA, others both fatty acids. ALA from flaxseed oil, chia seeds or walnuts remains a valuable part of the diet, even though its conversion to the long-chain forms is limited.

Anyone on anticoagulants, with a known heart rhythm disorder or planning a higher dose should coordinate their intake with a professional. A fish or seafood allergy, moreover, is not a problem that the marketing claim “molecularly distilled” reliably solves. Product-specific allergen information and, if needed, a suitable alternative matter more.

What the omega-3 index tells you

The omega-3 index is the share of EPA and DHA among the measured fatty acids in red blood cells. It responds less to individual meals in the short term than many plasma values do and can give information about supply over the past weeks to months.

Values below 4 percent, between 4 and 8 percent and above 8 percent are often discussed for risk classification. These proposed ranges are based largely on associations with health events. A value above 8 percent is no guarantee of heart protection and not a universally confirmed optimum for all organs.

A repeat test after about three to four months can show whether the share has changed. On its own, it proves neither a clinical benefit nor that a further dose increase makes sense. Nor does a red blood cell value directly reflect the fatty acid composition of every brain or heart tissue.

Triglycerides, ApoB or other values answer additional questions about metabolism and cardiovascular risk. A raised CRP level should be assessed in its own context. The combination of “low index plus high CRP” is not a validated automatic treatment algorithm.

Judging your supply in context

For many decisions, a careful look at diet, product and the reason for taking it is enough to start with. A test can add to a specific question, but it should have a consequence: which decision would actually turn out differently because of the result?

Anyone taking a supplement for a particular problem should also keep track of that problem. For triglycerides, that is a different assessment than for mood or vision complaints. A single universal measure of success would hide these differences.

Frequently asked questions

Is EPA better than DHA for depression?

Older meta-analyses provide stronger evidence for EPA-dominant preparations. That argues for looking closely at the formulation, but it does not replace individual treatment and does not guarantee success.

How does EPA affect inflammation?

EPA changes the available starting materials for certain signaling molecules and supplies E-series resolvins, among others. What clinical effect results depends on the specific context.

Why is DHA important for the brain?

DHA is one of the membrane components of nerve cells and is especially relevant during development. This basic role, however, does not prove that extra amounts improve memory when supply is already adequate.

What ratio should be on the label?

There is no best ratio for everyone. What matters more are the actual amounts of EPA and DHA and the data for the specific purpose.

How is the index different from a plasma value?

The index measures EPA and DHA in red blood cells and changes more slowly. Plasma values depend more on short-term influences. Both have to be interpreted in light of the question being asked.

Can you get it directly without fish oil?

Yes, suitable algal oils provide DHA and, depending on the product, EPA. The label should state the amount of each fatty acid. Algal oil is not automatically free of all quality problems, so product testing matters here too.

What does research show on high-dose EPA for the heart?

For icosapent ethyl, there is one large positive trial in selected high-risk patients. The benefits and risks of this drug treatment cannot be carried over to just any omega-3 supplement.

Is DHA more important during pregnancy?

DHA plays a special role in the development of the brain and retina. An additional intake of about 200 mg daily is often discussed, depending on diet and current recommendations. The specific supply should be assessed as part of prenatal care.

Sources from the original material

The following references were taken over from the source material and have not been fully and independently checked for this draft.

• Xiao Y, Chen Y, Pietzner A, Elbelt U, Fan Z, Weylandt KH (2024). Circulating Omega-3 Polyunsaturated Fatty Acids Levels in Coronary Heart Disease: Pooled Analysis of 36 Observational Studies. Nutrients, 16(11). https://doi.org/10.3390/nu16111610 · Source
• Lee Y, Lee L, Zhang L, Zhou Q (2024). Association between fatty acid intake and age-related macular degeneration: a meta-analysis. Frontiers in nutrition, 11, 1403987. https://doi.org/10.3389/fnut.2024.1403987 · Source
• Bernasconi AA, Wiest MM, Lavie CJ, Milani RV, Laukkanen JA (2021). Effect of Omega-3 Dosage on Cardiovascular Outcomes: An Updated Meta-Analysis and Meta-Regression of Interventional Trials. Mayo Clinic proceedings, 96(2), 304-313. https://doi.org/10.1016/j.mayocp.2020.08.034 · Source
• Sublette ME, Ellis SP, Geant AL, Mann JJ (2011). Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. The Journal of Clinical Psychiatry, 72(12), 1577-1584. https://doi.org/10.4088/JCP.10m06634 · Source
• Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM (2019). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. The New England Journal of Medicine, 380(1), 11-22. https://doi.org/10.1056/NEJMoa1812792 · Source